{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:28:19Z","timestamp":1722893299742},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1038\/sj.bjc.6601377","type":"journal-article","created":{"date-parts":[[2003,11,11]],"date-time":"2003-11-11T18:44:36Z","timestamp":1068576276000},"page":"1860-1864","source":"Crossref","is-referenced-by-count":10,"title":["A phase II irinotecan\u2013cisplatin combination in advanced pancreatic cancer"],"prefix":"10.1038","volume":"89","author":[{"name":"on behalf of the Pancreatic Trials Team","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Markham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D D","family":"Stocken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A B","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,11,11]]},"reference":[{"key":"BF6601377_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<654::AID-CNCR46>3.0.CO;2-V","volume":"78","author":"JD Ahlgren","year":"1996","unstructured":"Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer Suppl 78: 654\u2013663","journal-title":"Cancer Suppl"},{"key":"BF6601377_CR2","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/S0959-8049(97)10090-9","volume":"34","author":"HJ Andreyev","year":"1998","unstructured":"Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastro-intestinal malignancies? Eur J Cancer 34: 2132\u20132133","journal-title":"Eur J Cancer"},{"key":"BF6601377_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1749-6632.1996.tb26398.x","volume":"803","author":"JP Armand","year":"1996","unstructured":"Armand JP, Terret C, Couteau C, Rixe O (1996) CPT-11. The European experience. Ann N Y Acad Sci 803: 282\u2013291","journal-title":"Ann N Y Acad Sci"},{"key":"BF6601377_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00001813-199606000-00010","volume":"7","author":"MC Bissery","year":"1996","unstructured":"Bissery MC, Vrignaud P, Lavelle F, Chabot GG (1996) Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7: 437\u2013460","journal-title":"Anticancer Drugs"},{"key":"BF6601377_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/bjs.1800820137","volume":"82","author":"SR Bramhall","year":"1995","unstructured":"Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP (1995) Treatment and survival in 13\u2009560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study (see comments). Br J Surg 82: 111\u2013115","journal-title":"Br J Surg"},{"key":"BF6601377_CR6","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1200\/JCO.2001.19.15.3447","volume":"19","author":"SR Bramhall","year":"2001","unstructured":"Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomised trial. J Clin Oncol 19: 3445\u20133447","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR7","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol 15: 2403\u20132413","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/bjc.1996.18","volume":"73","author":"J Carmichael","year":"1996","unstructured":"Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101\u2013105","journal-title":"Br J Cancer"},{"key":"BF6601377_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/sj.bjc.6690568","volume":"80","author":"S Cascinu","year":"1996","unstructured":"Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Pessi MA, Fusco V, Luporini G, Cellerino R, Catalano G (1996) A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the study of Digestive Tract Cancer (GISCAD). Br J Cancer 80: 1595\u20131598","journal-title":"Br J Cancer"},{"key":"BF6601377_CR10","first-page":"6","volume":"26","author":"D Cunningham","year":"1999","unstructured":"Cunningham D, Glimelius B (1999) A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 26: 6\u201312","journal-title":"Semin Oncol"},{"key":"BF6601377_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/JCO.2000.18.1.195","volume":"18","author":"MJA de Jonge","year":"2000","unstructured":"de Jonge MJA, Verweij J, de Bruijn P, Brouwer E, Mathijessen RHJ, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A (2000) Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 18: 195","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/bjc.1996.241","volume":"73","author":"TR Evans","year":"1996","unstructured":"Evans TR, Lofts FJ, Mansi JL, Glees JP, Dalgleish AG, Knight MJ (1996) A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73: 1260\u20131264","journal-title":"Br J Cancer"},{"key":"BF6601377_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.1993.11.1.196","volume":"11","author":"D Gandia","year":"1993","unstructured":"Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A, Herait P (1993) CPT-11 induced cholinergic effects in cancer patients. J Clin Oncol 11: 196\u2013197","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1200\/JCO.1999.17.2.585","volume":"17","author":"M Hidalgo","year":"1999","unstructured":"Hidalgo M, Castellano D, Paz Ares L, Gravalos C, Diaz Puente M, Hitt R, Alonso S, Cortes Funes H (1999) Phase I\u2013II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585\u2013592","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR15","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.2003.02.147","volume":"21","author":"DH Ilson","year":"2003","unstructured":"Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD (2003) Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21: 2926\u20132932","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR16","first-page":"202","volume":"7","author":"F Kanzawa","year":"2001","unstructured":"Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, Nishio K (2001) In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 7: 202\u2013209","journal-title":"Clin Cancer Res"},{"key":"BF6601377_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1634\/theoncologist.6-6-488","volume":"6","author":"P Kozuch","year":"2001","unstructured":"Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, marino J, De Gregorio P, Bruckner HW (2001) Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and non-crossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6: 488\u2013495","journal-title":"Oncologist"},{"key":"BF6601377_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.2002.20.1.81","volume":"20","author":"RHJ Mathijssen","year":"2002","unstructured":"Mathijssen RHJ, Verweij J, de Jonge MJA, Nooter K, Stoter G, Sparreboom A (2002) Impact of bosy-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 20: 81\u201387","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85\u201391","journal-title":"N Engl J Med"},{"key":"BF6601377_CR20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2002.20.5.1182","volume":"20","author":"CMS Rocha Lima","year":"2002","unstructured":"Rocha Lima CMS, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR (2002) Irinotecan plus gemcitabine induces both radiographic and Ca19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20: 1182\u20131191","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y","volume":"78","author":"ML Rothenberg","year":"1996","unstructured":"Rothenberg ML, Abbruzzese JL, Moore ML, Portenoy RK, Robertson JM, Wanebo HJ (1996a) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (Suppl) 78: 627\u2013631","journal-title":"Cancer (Suppl)"},{"key":"BF6601377_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","volume":"85","author":"ML Rothenberg","year":"1999","unstructured":"Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer Jr CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85: 786\u2013795","journal-title":"Cancer"},{"key":"BF6601377_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a010600","volume":"7","author":"ML Rothenberg","year":"1996","unstructured":"Rothenberg ML, Moore MJ, Cripps MC, Anderson JS, Portenoy RK, Burris HA, Green MR, Tarasoff PG, Brown TD, Casper ES, Storniolo A-M, Von Hoff DD (1996b) A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 7: 347\u2013353","journal-title":"Ann Oncol"},{"key":"BF6601377_CR24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/sj.bjc.6600553","volume":"87","author":"S Slater","year":"2002","unstructured":"Slater S, Shamash J, Wilson P, Gallagher CJ, Slevin ML (2002) Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers \u2013 a new active regimen. Br J Cancer 87: 850\u2013853","journal-title":"Br J Cancer"},{"key":"BF6601377_CR25","first-page":"703","volume":"9","author":"AK Souid","year":"2003","unstructured":"Souid AK, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD (2003) Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res 9: 703\u2013710","journal-title":"Clin Cancer Res"},{"key":"BF6601377_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0006-291X(92)92351-W","volume":"188","author":"S Takeda","year":"1992","unstructured":"Takeda S, Shimazoe T, Kuga H, Sato K, Kono A (1992) Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11. Biochem Biophys Res Commun 188: 70\u201377","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6601377_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organisation for Research and Treatment of Cancer, National cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BF6601377_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","volume":"6","author":"DJ Wagener","year":"1995","unstructured":"Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu Boue A, Verweij J (1995) Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study (see comments). Ann Oncol 6: 129\u2013132","journal-title":"Ann Oncol"},{"key":"BF6601377_CR29","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1200\/JCO.1997.15.6.2414","volume":"15","author":"RP Whitehead","year":"1997","unstructured":"Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS (1997) Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 15: 2414\u20132419","journal-title":"J Clin Oncol"},{"key":"BF6601377_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/bjc.1997.17","volume":"75","author":"SJ Wigmore","year":"1997","unstructured":"Wigmore SJ, Plester CE, Richardson RA, Fearon KC (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75: 106\u2013109","journal-title":"Br J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601377","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:53:38Z","timestamp":1684414418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["BF6601377"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601377","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}